BioSpace

11/12/2024

Will you be at Biotech Showcase in January? The agenda has been published, and we're excited that BioSpace's Head of Insights, Lori Ellis will be moderating an essential discussion on the women's health gap and the role investment could play.

https://hubs.li/Q02_gQRw0

11/12/2024

Around 25 companies have gone public this year, most of them in the early months. Most have tumbled from their original offer price.

Around 25 companies have gone public this year, most of them in the early months. Most have tumbled from their original offer price.

11/12/2024

By far, the largest acquisition of 2024 was Novo Holdings’ yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion. Outside of that, the leading pharmaceutical companies kept to less than $5 billion per deal.

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion. Outside of that, the leading pharmaceutical companies kept to less than $5 billion per deal.

11/12/2024

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.

11/12/2024

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech obtained the candidate when it bought Biotheus last month in an acquisition deal that could reach up to $950 million.

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech obtained the candidate when it bought Biotheus last month in an acquisition deal that could reach up to $950 million.

11/12/2024

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines.

11/12/2024

Cellectar downsizes by 60% as it explores strategic options for cancer drug; layoffs expected to be completed in Q4.

Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.

11/12/2024

🎙️New on the Weekly: GSK, Gilead and Arcellx, Vertex and more present new data at the ASH annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward accelerated approval in Huntington’s disease.

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel…

10/12/2024

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.

10/12/2024

Belharra Therapeutics has cut 21 employees, leaving it with 30 people. Get more details on this and other workforce reductions in our layoff tracker.

Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.

10/12/2024

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.

10/12/2024

The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.

The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.

10/12/2024

Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from Johnson & Johnson and Legend’s Carvykti.

-T

Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.

10/12/2024

According to Jake Van Naarden, president of Eli Lilly and Company Oncology, the excess deaths could be due to the high rate of crossover in BRUIN CLL-321.

According to Jake Van Naarden, president of Lilly Oncology, the excess deaths could be due to the high rate of crossover in BRUIN CLL-321.

09/12/2024

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and explore strategic alternatives including a potential sale to maximize shareholder value.

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and explore strategic alternatives including a potential sale to maximize shareholder value.

09/12/2024

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie announced the Phase II failure of another key Cerevel asset, emraclidine.

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie announced the Phase II failure of another key Cerevel asset, emraclidine.

09/12/2024

Two CDMOs are letting go employees, with one also terminating its R&D and characterization services. Get the details in our layoff tracker.

Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.

09/12/2024

Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.

Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.